A new research carried out by Tel Aviv University in Israel provides a new and unique method for AIDS treatment, which is expected to develop a relevant vaccine or promote a one-time treatment for AIDS. This technology uses type B white blood cells, which can be genetically modified in patients and secrete neutralizing antibodies against AIDS virus (HIV). The study was published recently in the journal Nature. In the past 20 years, scientists have tried to turn AIDS from fatal to chronic treatment, which has improved the lives of many patients. However, there is still a long way to go to find a way to provide patients with a permanent cure. B cells are white blood cells responsible for producing antibodies against viruses, bacteria, etc. B cells form in the bone marrow, and when they mature, they enter the blood and lymphatic systems and from there into different parts of the body. So far, only a few scientists have been able to design B cells in vitro. In this study, ADI bazer Laboratory of Tel Aviv University developed a new method of one-time injection to treat AIDS for the first time. They genetically engineered B cells in the body to produce the required antibodies. Genetic engineering is completed with virus vectors derived from viruses. After engineering transformation, the virus vectors will not cause damage, but only bring the genes encoding antibodies into the B cells in the body. Researchers have been able to accurately introduce the gene encoding antibody into the required sites in the B cell genome. All treated model animals have responded, and their blood contains a large number of required antibodies, ensuring that they can effectively neutralize the HIV virus in the laboratory Petri dishes. The researchers said that they combined the ability of CRISPR to introduce genes into the required sites and the ability of virus vectors to bring the required genes to the required cells, thus transforming the B cells in patients. Researchers used two viral vectors of the adeno-associated virus (AAV) family, one to encode the required antibodies and the other to encode the CRISPR system. When CRISPR cuts into the desired site in the genome of B cells, it will guide the introduction of genes: encoding antibody genes that only target HIV. Researchers expect that in the next few years, drugs for the treatment of AIDS, other infectious diseases and some cancers caused by viruses (such as cervical cancer and head and neck cancer) will be produced in this way. (outlook new era)